Podcast

January 30, 2018

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Author(s):

Jaime Rosenberg

As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.

As health information technology (IT) tools are continually being introduced into the healthcare sphere, organizations are utilizing these tools to optimize care coordination, patient experience, and patient outcomes. Today, 2 organizations join us; 1 uses a 2-way text messaging platform to support patients and increase medication adherence, and the other is teaming up with a pharmaceutical company to develop health IT solutions in order to enhance precision medicine in oncology.

Listen below or through one of these podcast services:

iTunes: http://apple.co/2eYWTss

TuneIn: http://bit.ly/2gv7iwj

Stitcher: http://bit.ly/2gCqtFg

Related Videos

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Shaun McKenzie, MD

Screenshot of an interview with Rohan Garje, MD

Susan Escudier, MD, FACP

Sabarish Ayyappan, MD

Susan Escudier, MD, FACP

Screenshot of an interview with Evangelia Vlachou, MD

Screenshot of an interview with Barry Goy, MD

Debra Patt, MD, PhD, MBA, MPH

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

Related Content

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

February 25th 2025

Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care

Pearl Steinzor Arthur L. Jenkins III, MD, FACS

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

lung cancer | Image credit: Crystal light - stock.adobe.com

March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.

February 18th 2025

Varied Access: The Pharmacogenetic Testing Coverage Divide

Brooke McCormick Jai N. Patel, PharmD

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Karen Winkfield, MD, PhD

March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD

Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions